Our Affiliate System

We are building one organization with affiliates in two regions. Our parent company, now known as Prisma Health, supports both affiliates with overall direction and leadership as we continue to align. We will soon share one brand across the entire organization to better reflect this. The rebranded Palmetto Health-USC Medical Group will continue to operate as a joint venture between the Midlands affiliate and the USC School of Medicine.

Learn more
We are becoming Prisma Health in early 2019

Rare Tumor Center

Rare cancers. Unique options.

Patients with rare cancers – and limited treatments – have significantly expanded options. GHS’ Rare Tumor Center is the nation’s first center dedicated exclusively to the treatment and research of rare cancers.

GHS, like most nationally ranked cancer programs, has clinical research studies for the nation’s most common malignancies such as cancers of the breast, lung, colon and prostate. What’s been missing nationally is a program that offers a standardized approach for patients with uncommon tumors who have no evidence-based data for management and no clinical trials to address their treatment.

The center specializes in the management of rare tumors – those that affect anywhere from 150-5,000 patients each year.

  • Patients receive a standardized diagnostic evaluation, support services and streamlined approach to other disciplines such as surgery and radiology
  • Once initial evaluation is complete, the center will continue to stay in contact with the patient and the referring physician/provider to keep them up to date on potential treatment options
  • Patients will enroll in a protocol which will permit biopsy, tissue storage and clinical follow up
  • Molecular profiling allows physicians to more precisely target cancer based on each cancer’s unique genetic signature and is at the leading edge of personalized medicine
  • Molecular profiling will be performed and patients placed in an existing Phase I clinical trial


Next Generation Testing

Tumor Center patients who qualify to participate in a unique 18-month research study will receive molecular testing via the FoundationOne™ test. The test, which is provided through the newly announced strategic alliance with Foundation Medicine, utilizes next-generation sequencing to detect genomic alterations in more than 230 genes believed to be most relevant to the growth and spread of cancer.

To schedule a consultation for a patient or to speak to an intake nurse, please contact our intake coordinator, Melanie Durham, at (864) 455-3740.

Contact Us: (864) 455-7070

"This is Cutting-edge Medicine"

Lisa explains how her region-wide search for treatment options for her rare tumor led her right back home to Greenville.